Xilio Therapeutics (XLO) EV to CFO (2021 - 2026)

Xilio Therapeutics has disclosed EV to CFO across 6 years of filings, most recently posting 2.66 for Q2 2026.

• In Q2 2026, EV to CFO fell 168.73% year-over-year to 2.66; the TTM figure through Jun 2026 stood at 0.82 (down 119.59% YoY), while the FY2025 annual figure was 12.54, up 1888.15% from the prior year.
• EV to CFO came in at 2.66 for Q2 2026 at Xilio Therapeutics, down from 0.58 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 31.34 in Q4 2025 to a low of 2.66 in Q2 2026.
• Average EV to CFO over 5 years is 2.45, with a median of 0.47 recorded in 2024.
• Year-over-year, EV to CFO tumbled 611.55% in 2024 and jumped 3726.5% in 2025.
• Over 5 years, EV to CFO stood at 2.56 in 2022, then declined by 14.05% to 2.2 in 2023, then slumped by 62.75% to 0.82 in 2024, then jumped by 3726.5% to 31.34 in 2025, then slumped by 108.48% to 2.66 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 2.66 in Q2 2026, 0.58 in Q1 2026, and 31.34 in Q4 2025.